BSE filing, NSE: PPLPHARMA. Summary written from the filing by ALFA Finder's alert engine.
Piramal Pharma Ltd: key numbers
- Share price
- ₹242.61
- Market cap
- ₹32,300 Cr
- Revenue (annual)
- ₹8,869 Cr
- Net profit (annual)
- ₹-325.9 Cr
- P/E (TTM)
- -154.7×Sector 48.6×
- Promoter holding
- 34.80%+0.00% QoQ
- FII holding
- 13.65%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Piramal Pharma Ltd
All →Piramal Pharma Capital Structure Change
HDFC Mutual Fund schemes reduced their Piramal Pharma stake by 2.027% via open market sale on 28 October 2026. Holding fell from 7.015% to 4.988%.
Piramal Pharma Investor Presentation: Key Takeaways
Q2FY27 revenue ₹2,617 Cr (+28% YoY), EBITDA margin 14.7% (+372 bps), PAT ₹5 Cr vs loss of ₹99 Cr. FY27 revenue growth outlook raised to 19-20%.
Piramal Pharma Results Update
Piramal Pharma released its Q2/H1 FY27 press release reporting revenue of Rs. 2,617 crore for Q2 and Rs. 4,887 crore for H1, with EBITDA up 72%. The filing also upgrades FY27 revenue growth guidance to 19–20%.
Piramal Pharma Q2 FY27 Results: Turns Profitable, Net Profit ₹5 Cr
Piramal Pharma Ltd reported revenue from operations of ₹2,617 Cr (+28.1% YoY) and net profit of ₹5 Cr for Q2 FY27.
- Key figure
- Net profit ₹5 Cr
Piramal Pharma Other Announcement
The company filed its quarterly shareholding pattern for the period ended September 30, 2026. The report details equity distribution among promoters and public shareholders.
Piramal Pharma Board Meeting Date
Piramal Pharma Limited has scheduled a board meeting on October 27, 2026. The board will consider and approve unaudited financial results for the quarter ended September 30, 2026.
Other acquisition announcements
All →Advent Hotels International Acquisition Worth ₹5.38 Cr
Advent Hotels acquired 50% control of Advent Convention and Hotels International Pvt Ltd for Rs.5.38 Crore cash. The target will develop a Mumbai commercial project.
- Value
- ₹5.38 Cr
- Execution
- Indicative completion date stated as 17-11-2026
Phoenix Mills Acquisition Worth ₹373.9 Cr
Phoenix Mills' stake in subsidiary ISMDPL rose to 71.23% after ISMDPL bought back CPP Investments' shares. Consideration was Rs.373.88 Crore, paid on 18 November 2026.
- Value
- ₹373.9 Cr
AYM Syntex Acquisition
NCLT Mumbai sanctioned the amalgamation of Mandawewala Enterprises into AYM Syntex, effective on sanction. The formal order is awaited and will be disclosed when received.
ACCEL Acquisition Worth ₹3.01 Cr
Accel will buy 2,98,399 Secureinteli shares at ₹101 each, lifting its stake to 84.10%. Secureinteli becomes a subsidiary, a deal worth about ₹3.01 Crore.
- Value
- ₹3.01 Cr
Prestige Estates Projects Acquisition Worth ₹2.69 Cr
Prestige's subsidiary acquired 50% of Advent Convention for ₹2.69 Crore. The target holds 21,978 sq. m land in Mumbai for a ₹4,500 Crore commercial project.
- Value
- ₹2.69 Cr
- leasable area
- 1500000 sq. ft.
Insecticides (India) Acquisition Worth ₹3.54 Cr
Insecticides (India) invested Rs. 3.54 Crore for a 26% stake in FP Alpha Private Limited. The acquisition targets wind and solar captive power capacity in Gujarat.
- Value
- ₹3.54 Cr